Citius Oncology, Inc. Common Stock (CTOR) Stock Price
CTORStock
$0.78−63.42%52W
Market Cap$82.03M
P/E—
PEG Ratio—
Div yield—
Beta3.49
CTOR Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-42.06%
Price vs S&P 500 (4W)22.48%
VGM Score39.89
CTOR Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.07 | -$0.08 | -14.29%(-$0.01) | |
| Q1 2026 | -$0.01 | -$0.27 | -2600.00%(-$0.26) | |
| Q4 2025 | -$0.04 | -$0.06 | -50.00%(-$0.02) | |
| Q3 2025 | -$0.06 | -$0.06 | +0.00%(+$0.00) | |
| Q2 2025 | -$0.15 | -$0.08 | +46.67%(+$0.07) |
CTOR Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CTORCitius Oncology, Inc. Common Stock | — | — | D | $0.78 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About Citius Oncology, Inc. Common Stock
Citius Oncology is a biopharmaceutical company developing targeted cancer therapies through lower-risk approaches, including new formulations and expanded indications for approved drugs. The company leverages intellectual property and regulatory exclusivity to accelerate market entry while serving key cancer centers.